$MSB

MESABI TRUST (MSB): Results of Operations and Financial Condition

MESABI TRUST (MSB) filed an SEC Form 8-K — Results of Operations and Financial Condition. MESABI TRUST_July 30, 2026 0000065172 false 0000065172 2026-07-30 2026-07-30 ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest e

Original reporting
Published Jul 31, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$MSB
Neutral
medium confidence
Mentioned
$MSB
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MSBNeutralLow
01

Why it matters

The 8-K reports the royalty report and the cash royalty payment received, including base royalty, bonus royalty at $0, and a separate $222,083 payment to the Mesabi Land Trust. It also provides shipment tonnage for Q2 2026 versus Q2 2025 and reiterates that future royalties can vary materially due to operator decisions, customer schedules, and iron ore pricing.

02

Market read

Traders in MSB may use the reported royalty payment and the absence of bonus royalty to update near-term distribution expectations, while recognizing that pricing inputs and due diligence can change final outcomes.

03

What to watch

The filing notes royalties are based on estimated prices subject to change and subject to due diligence and verification, so the reported payment may not fully represent final economics for the period.

Relevance 7/10Novelty 5/10Timing: filed after-hours on 2026-07-31, reporting royalty payment received on 2026-07-30

Background

Mesabi Trust is a royalty trust tied to iron ore shipments from Northshore Mining (parented by Cleveland-Cliffs).

Company-level read

Ticker impact

$MSBNeutralMedium confidence
Context

Mesabi Trust disclosed receipt of a quarterly royalty report and royalty payment totaling $1,807,779 for the quarter ended June 30, 2026.

Expected impact

Likely limited immediate price impact unless traders were positioned for a bonus royalty or a materially different royalty level; focus is on distribution outlook.

Evidence & confidence

The 8-K provides concrete royalty payment and bonus royalty details, but it does not include guidance for future quarters beyond noting variability and due diligence.

Market effects

Highlights how iron ore pellet shipment volumes and pricing below a bonus threshold can suppress bonus royalties for royalty trusts.

No direct regional market linkage beyond Silver Bay, Minnesota shipment flows.

Iron ore pricing sensitivity is globally driven, but the filing is company-specific and does not add new macro information.

Counterpoint

Even with a $0 bonus royalty this quarter, the trust’s distributions may be more influenced by longer-run shipment volumes and pricing trends than by one quarter’s threshold outcome.

Key entities

  • MESABI TRUST

    Royalty trust reporting quarterly royalty receipts and related financial condition updates via Form 8-K.

  • Cleveland-Cliffs Inc.

    Parent company providing the royalty report based on Northshore Mining shipments and pricing assumptions.

  • Northshore Mining Company

    Iron ore pellet producer whose shipments determine Mesabi Trust royalty calculations.

  • Mesabi Land Trust

    Receives a stated portion of royalty payments ($222,083) as disclosed in the filing.

Related articles

$MSBMed

First Vietnamese bank surpasses $762mn in quarterly net interest income

Vietnam’s listed banks reported higher second-quarter 2026 net interest income versus the prior quarter, with only five banks declining. VietinBank led with a record VND20.7 trillion, first above VND20 trillion. BIDV, Vietcombank and VPBank also posted strong results. State Bank of Vietnam said system credit rose 8.38% to VND20.15 quadrillion by July 29.

$MSBMed

Mesoblast Shares Break Resistance Following Latest Milestone

Mesoblast (ASX: MSB) shares rose after the company said its Phase 3 MSB-DR004 trial for rexlemestrocel-L in chronic lower back pain reached its target of at least 300 treated patients. The randomized, placebo-controlled study compares an intradiscal injection vs sham and follows patients for 12 months. The update removes an execution risk and supports a regulatory catalyst timeline.

$MSBMed

MESABI TRUST (MSB): Results of Operations and Financial Condition

MESABI TRUST (MSB) filed an SEC Form 8-K — Results of Operations and Financial Condition. MESABI TRUST_July 14, 2026 0000065172 false 0000065172 2026-07-14 2026-07-14 ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest e

$TMCRMed

The Metals Royalty Company Announces Completion of First Production Blast at Mesabi Metallics

The Metals Royalty Company (NASDAQ:TMCR) said its Mesabi Metallics royalty asset in Nashwauk, Minnesota completed its first production blast on July 10, 2026, fracturing about 211,000 tons of ore and opening the first pit ramp. TMCR expects ore to feed DR-grade pellets under a 1.0% index-priced gross overriding royalty with a revenue floor, targeting first pellet production in H2 2026 and potential annual royalty cash flow of about $11 million at 7.28 Mtpa.

$MSBMed

Mesoblast Shares Lead ASX 200 Today: The Latest

Mesoblast (ASX: MSB) shares led ASX 200 gainers, up 4.91% to A$2.35, extending a two-week 24% rally. Bell Potter upgraded to Buy with a A$4.45 target. Mesoblast said it drew US$50m from a non-dilutive facility on June 25, and reported FDA BLA progress for Ryoncil (remestemcel-L) in late June and early July.

$MSBMedAI 8/10

Mesoblast Shares Lead The ASX 200 Into The Weekend

Mesoblast (ASX: MSB) shares rose 6.67% to A$2.24 after the company reported fourth-quarter net revenue of US$36 million for the three months ended 30 June 2026, above market expectations. Full-year revenue was US$115 million, driven by stronger US uptake of its Ryoncil therapy in paediatric transplant patients.